Current Medicinal Chemistry

Preface (Hot Topic: Iron Chelation and Human Diseases Guest Editor: Regis Leung-Toung)
pp. i-i(1)
Author: Leung-Toung, R.

Iron Chelator Research: Past, Present, and Future
pp. 983-995(13)
Authors: Tam, T.F.; Leung-Toung, R.; Li, W.; Wang, Y.; Karimian, K.; Spino, M.

An Overview of Iron Metabolism: Molecular and Cellular Criteria for the Selection of Iron Chelators
pp. 997-1004(8)
Authors: Crichton, R.R.; Ward, R.J.

The HAG Mechanism: A Molecular Rationale For The Therapeutic Application Of Iron Chelators In Human Diseases Involving the 2-Oxoacid Utilizing Dioxygenases
pp. 1005-1019(15)
Authors: Hanauske-Abel, H.M.; Popowicz, A.M.

The Role of Iron Chelation in Cancer Therapy
pp. 1021-1034(14)
Authors: Buss, J.L.; Torti, F.M.; Torti, S.V.

Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
pp. 1035-1049(15)
Authors: Lovejoy, D.B.; Richardson, D.R.

Emerging Understanding of the Advantage of Small Molecules such as Hydroxypyridinones in the Treatment of Iron Overload
pp. 1051-1064(14)
Authors: Hider, R.C.; Liu, Z.D.

Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670
pp. 1065-1076(12)
Authors: Nick, H.; Acklin, P.; Lattmann, R.; Buehlmayer, P.; Hauffe, S.; Schupp, J.; Alberti, D.

Hydroxyquinolines as Iron Chelators
pp. 1077-1084(8)
Authors: Pierre, J.; Baret, P.; Serratrice, G.